LEYLA MISSAGHI: Open Payments
NPI 1427693894 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 15 payments from 12 companies in 2025. Trend: 2023 $649 · 2024 $438 · 2025 $1,059
Food & beverage: $880Education: $179
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 3 | $204 |
| Syndax Pharmaceuticals, Inc. | 1 | $142 |
| GlaxoSmithKline, LLC. | 1 | $125 |
| Janssen Biotech, Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
| GENZYME CORPORATION | 1 | $104 |
| Lilly USA, LLC | 2 | $43 |
| PharmaEssentia USA Corporation | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
Products named: REVUFORJ, JEMPERLI, RYBREVANT, BREYANZI, LYNOZYFIC, SARCLISA, BESREMI, IMFINZI.
Industry payments across VA — which companies pay providers there.
